» Articles » PMID: 36084050

Adoption of HIV Pre-exposure Prophylaxis Among Women at High Risk of HIV Infection in Kenya

Overview
Journal PLoS One
Date 2022 Sep 9
PMID 36084050
Authors
Affiliations
Soon will be listed here.
Abstract

In 2017, Kenya became one of the first African countries to provide pre-exposure prophylaxis (PrEP) in its national HIV prevention plan. We sought to characterize factors associated with PrEP uptake and persistence among a cohort of women at risk of HIV infection during the early stages of PrEP scale-up in Kenya. HIV-negative women ≥18 years with ≥2 sexual partners in the past 4 weeks were recruited as part of an ongoing cluster randomized trial of an HIV self-testing intervention. PrEP use was assessed at baseline and at 6- and 12-month follow-up visits. Between June 2017 and August 2018, 2,086 were enrolled and had complete baseline data. 138 (6.6%) reported PrEP use during the first year of the study. Although PrEP use increased, persistence on PrEP was low, and less than half of individuals reported continuing PrEP at follow-up visits. In multivariate analyses, PrEP use was associated with recent STIs, having an HIV-positive primary partner, having regular transactional sex in the past 12 months, and being a female sex worker. In the early stages of PrEP scale-up in Kenya, uptake increased modestly among women with risk factors for HIV infection, but overall uptake and persistence was low.

Citing Articles

High retention among key populations initiated on HIV pre-exposure prophylaxis in Kigali City, Rwanda.

Munyaneza A, Bhutada K, Shi Q, Zotova N, Nsereko E, Muhoza B J Int AIDS Soc. 2024; 27(11):e26392.

PMID: 39568160 PMC: 11578929. DOI: 10.1002/jia2.26392.


Pre-exposure prophylaxis implementation gaps among people vulnerable to HIV acquisition: a cross-sectional analysis in two communities in western Kenya, 2021-2023.

Romo M, Schluck G, Kosgei J, Akoth C, Bor R, Langat D J Int AIDS Soc. 2024; 27(11):e26372.

PMID: 39496511 PMC: 11534481. DOI: 10.1002/jia2.26372.


Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.

Gray G, Mngadi K, Lavreys L, Nijs S, B Gilbert P, Hural J Lancet Infect Dis. 2024; 24(11):1201-1212.

PMID: 39038477 PMC: 11512672. DOI: 10.1016/S1473-3099(24)00358-X.


Uptake of retroviral pre-exposure prophylaxis and its associated factors among female sex workers, Northwest Ethiopia.

Shibesh B, Admas A, Lake A, Getu S, Worede D AIDS Res Ther. 2023; 20(1):77.

PMID: 37926821 PMC: 10626692. DOI: 10.1186/s12981-023-00573-5.

References
1.
Mboup A, Behanzin L, Guedou F, Geraldo N, Goma-Matsetse E, Giguere K . Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study. J Int AIDS Soc. 2019; 21(11):e25208. PMC: 6287093. DOI: 10.1002/jia2.25208. View

2.
Pintye J, Beima-Sofie K, MakabongO P, Njoroge A, Trinidad S, Heffron R . HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Pre-Exposure Prophylaxis During Pregnancy. AIDS Patient Care STDS. 2018; 32(12):538-544. PMC: 6300042. DOI: 10.1089/apc.2018.0058. View

3.
Kinuthia J, Pintye J, Abuna F, Mugwanya K, Lagat H, Onyango D . Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2019; 7(1):e38-e48. PMC: 11498332. DOI: 10.1016/S2352-3018(19)30335-2. View

4.
Cowan F, Davey C, Fearon E, Mushati P, Dirawo J, Chabata S . Targeted combination prevention to support female sex workers in Zimbabwe accessing and adhering to antiretrovirals for treatment and prevention of HIV (SAPPH-IRe): a cluster-randomised trial. Lancet HIV. 2018; 5(8):e417-e426. DOI: 10.1016/S2352-3018(18)30111-5. View

5.
Celum C, Delany-Moretlwe S, Baeten J, van der Straten A, Hosek S, Bukusi E . HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019; 22 Suppl 4:e25298. PMC: 6643076. DOI: 10.1002/jia2.25298. View